首站-论文投稿智能助手
典型文献
Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells
文献摘要:
Non-alcoholic fatty liver disease(NAFLD)is emerging as an epidemic risk factor for hepatocellular carcinoma(HCC).The progression of NAFLD to HCC is closely associated with paracrine communication among hepatic cells.Vascular endothelial growth factor A(VEGFA)plays a key role in NAFLD and HCC;however,the cellular communication of VEGFA in the pathological transition from NAFLD to HCC remains unclear.Here,we found that VEGFA elevation was considerably distributed in hepatocytes of clinical and murine NAFLD-HCC specimens.Notably,progression from NAFLD to HCC was attenuated in hepatocyte-specific deletion of Vegfa(VegfaAhep)mice.Mechanistically,VEGFA activated human hepatic stellate cell(HSC)LX2 into a fibrogenic phenotype via VEGF-VEGFR signaling in fatty acid medium,and HSC activation was largely attenuated in Vegfa△hep mice during NAFLD-HCC progression.Additionally,a positive correlation between VEGFA and hepatic fibrosis was observed in the NAFLD-HCC cohort,but not in the HBV-HCC cohort.Moreover,LX2 cells could be activated by conditioned medium from NAFLD-derived organoids,but not from HBV livers,whereas this activation was blocked by a VEGFA antibody.In summary,our findings reveal that hepatocyte-derived VEGFA contributes to NAFLD-HCC development by activating HSCs and highlight the potential of precisely targeting hepatocytic VEGFA as a promising therapeutic strategy for NAFLD-HCC.
文献关键词:
作者姓名:
Hao Shen;Han Yu;Qian-yu Li;Ya-ting Wei;Jing Fu;Hui Dong;Dan Cao;Lin-na Guo;Lei Chen;Yuan Yang;Ying Xu;Meng-chao Wu;Hong-yang Wang;Yao Chen
作者机构:
International Cooperation Laboratory on Signal Transduction,National Center for Liver Cancer,Ministry of Education Key Laboratory on signaling Regulation and Targeting Therapy of Liver Cancer,Shanghai Key Laboratory of Hepato-biliary Tumor Biology,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University/NAVAL Medical University,Shanghai 200433,China;Department of Pathology,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Institute of Metabolism and Integrative Biology,Fudan University,Shanghai 200438,China;Third Department of Hepatic Surgery,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University,Shanghai 200433,China
引用格式:
[1]Hao Shen;Han Yu;Qian-yu Li;Ya-ting Wei;Jing Fu;Hui Dong;Dan Cao;Lin-na Guo;Lei Chen;Yuan Yang;Ying Xu;Meng-chao Wu;Hong-yang Wang;Yao Chen-.Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells)[J].中国药理学报(英文版),2022(11):2917-2928
A类:
Vegfa,VegfaAhep,hepatocytic
B类:
Hepatocyte,derived,VEGFA,accelerates,progression,alcoholic,fatty,disease,hepatocellular,carcinoma,via,activating,hepatic,stellate,cells,Non,NAFLD,emerging,epidemic,risk,HCC,closely,associated,paracrine,communication,among,Vascular,endothelial,growth,plays,key,role,however,pathological,transition,from,remains,unclear,Here,found,that,elevation,was,considerably,distributed,hepatocytes,clinical,murine,specimens,Notably,attenuated,specific,deletion,mice,Mechanistically,activated,human,LX2,into,fibrogenic,phenotype,VEGFR,signaling,acid,medium,activation,largely,during,Additionally,positive,correlation,between,fibrosis,observed,cohort,HBV,Moreover,could,by,conditioned,organoids,livers,whereas,this,blocked,antibody,In,summary,our,findings,reveal,contributes,development,HSCs,highlight,potential,precisely,targeting,promising,therapeutic,strategy
AB值:
0.495407
相似文献
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer
Junru Feng;Hui Lu;Wenhao Ma;Wenjing Tian;Zhuan Lu;Hongying Yang;Yongping Cai;Pengfei Cai;Yuchen Sun;Zilong Zhou;Jiaqian Feng;Jiazhong Deng;Ying Shu;Kun Qu;Weidong Jia;Ping Gao;Huafeng Zhang-Anhui Key Laboratory of Hepatopancreatobiliary Surgery,Department of General Surgery,Anhui Provincial Hospital,The First Affiliated Hospital of USTC,Division of Life Science and Medicine,University of Science and Technology of China,Hefei 230027,China;Hefei National Laboratory for Physical Sciences at Microscale,The Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease,School of Basic Medical Sciences,Division of Life Science and Medicine,University of Science and Technology of China,Hefei 230027,China;Shenzhen People's Hospital,Second Clinical Medical College of Jinan University,First Affiliated Hospital of Southern University of Science and Technology,Shenzhen 518000,China;Department of Pathology,School of Medicine,Anhui Medical University,Hefei 230032,China;School of Medicine and Institutes for Life Sciences,South China University of Technology,Guangzhou 510006,China
The S100 calcium binding protein A11 promotes liver fibrogenesis by targeting TGF-β signaling
Tingting Zhu;Linqiang Zhang;Chengbin Li;Xiaoqiong Tan;Jing Liu;Huiqin Li;Qijing Fan;Zhiguo Zhang;Mingfeng Zhan;Lin Fu;Jinbo Luo;Jiawei Geng;Yingjie Wu;Xiaoju Zou;Bin Liang-Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences&Yunnan Province,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,Yunnan 650223,China;Kunming College of Life Science,University of Chinese Academy of Sciences,Kunming,Yunnan 650204,China;Center for Life Sciences,School of Life Sciences,Yunnan University,Kunming,Yunnan 650091,China;School of Traditional Chinese Medicine,Yunnan University of Chinese Medicine,Kunming,Yunnan 650500,China;Infectious Diseases Department and Hepatic Diseases Department,The First People's Hospital of Yunnan Province,Kunming,Yunnan 650034,China;Infectious Diseases Department and Hepatic Diseases Department,The Affiliated Hospital of Kunming University of Science and Technology,Kunming,Yunnan 650034,China;School of Laboratory Animal&Shandong Laboratory Animal Center,Science and Technology Innovation Center,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan,Shandong 250021,China;Institute for Genome Engineered Animal Models of Human Diseases,National Center of Genetically Engineered Animal Models for International Research,Liaoning Provence Key Lab of Genome Engineered Animal Models Dalian Medical University,Dalian,Liaoning 116044,China
Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis
Liu Jiaye;Tian Ye;Fu Xia;Mu Chunyang;Yao Menglin;Ni Yinyun;Liu Yong;Li Zhihui-Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China;Laboratory of Thyroid and Parathyroid Diseases, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China;State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan 610000, China;Respiratory Health Institute, Frontiers Science Center for Disease Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China;Department of Ultrasound, West China Hospital of Sichuan University, Chengdu, Sichuan 610000, China;Department of Outpatients, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China;Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China;Department of Gastroenterological Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China
Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1
Li Mingzhe;Zhou Jiaxin;Zhang Zhengkui;Li Jisong;Wang Feng;Ma Ling;Tian Xiaodong;Mao Zebin;Yang Yinmo-Department of General Surgery, Peking University First Hospital, Beijing 100034, China;Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016, China;Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China;Department of Surgical Oncology, Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital, Capital Medical University), Beijing 100038, China;Department of Medical Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100191, China
Mongolian medicine in treating type 2 diabetes mellitus combined with nonalcoholic fatty liver disease via FXR/LXR-mediated P2X7R/NLRP3/NF-κB pathway activation
Shuyin Bao;Xiuzhi Wang;Qianqian Ma;Chengxi Wei;Jixing Nan;Wuliji Ao-Institute of Pharmaceutical Chemistry and Pharmacology,Inner Mongolia Minzu University,Tongliao 028000,China;Inner Mongolia Key Laboratory of Mongolian Medicine Pharmacology for Cardio-Cerebral Vascular System,Tongliao 028000,China;Jilin Key Laboratory for Traditional Chinese Korean Medicine,College of Pharmacy,Yanbian University,Yanji 133002,China;Department of Medicines and Foods,Tongliao Vocational College,Tongliao 028000,China;Research and development center,Inner Mongolia Research Institute of Traditional Mongolian Medicine Engineering Technology,Tongliao 028000,China;Mongolian Medicine R&D National Local Union Engineering Research Center,Inner Mongolia Minzu University,Tongliao 028000,China
Antrodia cinnamomea exerts an anti-hepatoma effect by targeting PI3K/AKT-mediated cell cycle progression in vitro and in vivo
Yan Zhang;Pin Lv;Junmei Ma;Ning Chen;Huishan Guo;Yan Chen;Xiaoruo Gan;Rong Wang;Xuqiang Liu;Sufang Fan;Bin Cong;Wenyi Kang-Hebei Key Laboratory of Forensic Medicine,College of Forensic Medicine,Hebei Medical University,Shijiazhuang 050017,China;Hebei Food Safety Key Laboratory,Hebei Food Inspection and Research Institute,Shijiazhuang 050091,China;Cardiovascular Medical Science Center Department of Cell Biology,Hebei Medical University,Shijiazhuang 050017,China;National R&D Center for Edible Fungus Processing Technology,Henan University,Kaifeng 475004,China;Research Unit of Digestive Tract Microecosystem Pharmacology and Toxicology,Chinese Academy of Medical Sciences,Beijing 100730,China
Inhibition of ASCT2 induces hepatic stellate cell senescence with modified proinflammatory secretome through an IL-1α/NF-κB feedback pathway to inhibit liver fibrosis
Feixia Wang;Zhanghao Li;Li Chen;Ting Yang;Baoyu Liang;Zili Zhang;Jiangjuan Shao;Xuefen Xu;Guoping Yin;Shijun Wang;Hai Ding;Feng Zhang;Shizhong Zheng-Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica,School of Pharmacy,Nanjing University of Chinese Medicine,Nanjing 210023,China;Department of Anesthesiology,Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine,Nanjing 210003,China;College of Traditional Chinese Medicine,Shandong University of Traditional Chinese Medicine,Jinan 250035,China;Department of General Surgery,Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine,Nanjing 210003,China
Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease
Jie Tong;Dongjie Li;Hongbo Meng;Diyang Sun;Xiuting Lan;Min Ni;Jiawei Ma;Feiyan Zeng;Sijia Sun;Jiangtao Fu;Guoqiang Li;Qingxin Ji;Guoyan Zhang;Qirui Shen;Yuanyuan Wang;Jiahui Zhu;Yi Zhao;Xujie Wang;Yi Liu;Shenxi Ouyang;Chunquan Sheng;Fuming Shen;Pei Wang-Department of Pharmacy,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Institute of Nuclear Medicine,Tongji University School of Medicine,Shanghai 200072,China;Department of General Surgery,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Department of Pharmacology,School of Pharmacy,Naval Medical University/Second Military Medical University,Shanghai 200433,China;Department of Pharmacy,Shanghai Fourth People's Hospital,Tongji University School of Medicine,Shanghai 200081,China;Shanghai Key Laboratory of Regulatory Biology,Institute of Biomedical Sciences and School of Life Sciences,East China Normal University,Shanghai 200241,China;Chemical Biology Research Center School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325000,China;Department of Medicinal Chemistry,School of Pharmacy,Naval Medical University/Second Military Medical University,Shanghai 200433,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。